OMIC: Multiplikator rega marang pendapatan Singular Genomics Systems, Inc.
The rolling P/S of Singular Genomics Systems (OMIC) helps identify asset overheating, with 18.80 representing the current metric value. The Singular Genomics Systems (OMIC) business is protected by a complex NGS patent portfolio and strict FDA oversight. Production facilities consistently output analyzers featuring updated chip lithography. The firm's technologies automate laboratories, replacing manual labor with autonomous genetic sequencing.
Rincian metrik lan analitis perusahaan Singular Genomics Systems Inc (OMIC)
- rega saham lan konsensus proyeksi valuasi:
- informasi kapitalisasi pasar:
- data kapitalisasi buku:
- statistik kawajiban utang lan likuiditas:
Utang marang Modal Singular Genomics Systems|OMIC - Utang jangka dawa marang ekuitas|Rasio utang jangka cendhak marang ekuitas Singular Genomics Corp|OMIC - Gunggung utang perusahaan|Utang-utang marang aset resik Singular Genomics Systems Inc|OMIC - Utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan Singular Genomics|Koefisien jangkoan perantara singulargenomics.com
- data bathi lan kelipatan valuasi:
OMIC - Penghasilan resik|Penghasilan resik sing dikarepake Singular Genomics Systems|OMIC - Rasio rega marang bathi|Kapitalisasi marang proyeksi bathi Singular Genomics Systems, Inc.|OMIC - Pangali rega marang bathi tumrap wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Singular Genomics Systems Inc|OMIC - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi resik saben saham sajrone patang kuartal pungkasan Singular Genomics|OMIC - Bathi resik saben saham sajrone 12 wulan pungkasan|Kacepetan wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan singulargenomics.com|OMIC - Wutah bathi ing taun lumaku|Prakiraan wutah bathi resik saben saham ing taun ngarep Singular Genomics Systems
- data total pendapatan lan volume dodolan:
Analisis umum perusahaan:OMIC, singulargenomics.com
Amidst the fierce competition of Singular Genomics Systems (OMIC) against sequencing market monopolists, the current price-to-sales ratio reflects the market's valuation of the company's expansion potential. This metric is calculated as the ratio of market capitalization to annual revenue, allowing investors to determine the premium paid per unit of sales and assess business resilience during periods of high volatility and technological pressure from competitors.
Perusahaan pesaing
TEM (Tempus AI) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S QGEN (Qiagen)|Multiplikator rega marang pendapatan Ionis Pharmaceuticals, Inc.|Repligen Corp. - Multiplikator P/S|Rega marang dodolan Avidity Corp|CRISPR Therapeutics AG (CRSP) - Rasio rega marang pendapatan|Rasio kapitalisasi marang pendapatan WGS|Rasio rega marang pendapatan Ultragenyx|Rega marang dodolan Beam Therapeutics Inc BEAM|Rasio rega marang pendapatan Sarepta Therapeutics Inc (SRPT)|Kapitalisasi marang pendapatan Twist Bioscience Corp TWST|Multiplikator P/S TXG (10x Genomics, Inc.)|Koefisien rega marang pendapatan intelliatx.com (NTLA)|Stoke Therapeutics, Inc. - Multiplikator P/S|BioLife Solutions Inc (BLFS) - Kapitalisasi marang pendapatan|Wave Life Sciences Corp (WVE) - Rasio rega marang pendapatan|MAZE - Koefisien rega marang pendapatan|Kapitalisasi marang pendapatan SION|PRME: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Taysha Gene Therapies, Inc. (TSHA)|Koefisien rega marang pendapatan uniQure NV|MeiraGTx PLC - Kapitalisasi marang pendapatan|REGENXBIO Corp (RGNX) - Rega marang dodolan|SLDB - Rasio rega marang pendapatan|Koefisien rega marang pendapatan ocugen.com OCGN|PACB (PacBio) - Kapitalisasi marang pendapatan|BNTC: Kapitalisasi marang volume dodolan|DSGN (Design Pharma) - Multiplikator P/S|Rega marang dodolan Rocket Corp RCKT|Rasio rega marang pendapatan 4D Molecular Therapeutics (FDMT)|Kapitalisasi marang pendapatan lexeotx.com LXEO|Rasio rega marang pendapatan Korro Bio KRRO|Koefisien rega marang pendapatan Editas Medicine Inc (EDIT)|SLN - Rasio rega marang pendapatan|Rega marang dodolan ProQR Therapeutics N.V.|codexis.com (CDXS) - Rasio rega marang pendapatan|Kapitalisasi marang pendapatan sangamo.com|NAUT (Nautilus Biotechnology, Inc.) - Multiplikator P/S|Metagenomi Inc. (MGX) - Koefisien rega marang pendapatan|Multiplikator P/S DTIL|Kapitalisasi marang pendapatan generationbio.com GBIO|Multiplikator P/S BOLD (Boundless Bio, Inc.)|XCUR: Rasio kapitalisasi marang pendapatan|IMNN - Rasio rega marang pendapatan|PHIO (Phio Pharmaceuticals) - Rasio kapitalisasi marang pendapatan|MBIO: Multiplikator P/S|TransCode Therapeutics, Inc. (RNAZ) - Multiplikator P/S|Rasio rega marang pendapatan Bionano Genomics Inc.|adnas.com (APDN) - Koefisien rega marang pendapatan|Multiplikator P/S BLUE|Koefisien rega marang pendapatan immunoprecise.com|Rasio rega marang pendapatan Omega OMGA|RGLS: Rasio kapitalisasi marang pendapatan|Syros Pharmaceuticals - Multiplikator P/S|Multiplikator rega marang pendapatan telesisbio.com (TBIO)|TCON (TRACON Pharmaceuticals, Inc.) - Kapitalisasi marang pendapatan|Unity Biotechnology Inc. (UBX) - Multiplikator P/S
